The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian CarcinomaMikhail S. Chesnokov, Ilana Chefetz|Cancers|2021Cited by 29
Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian CancerMikhail S. Chesnokov, Ilana Chefetz|International Journal of Molecular Sciences|2022Cited by 11
Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancerMikhail S. Chesnokov, Ilana Chefetz|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1